SciTech Development, Inc.’s Post

View organization page for SciTech Development, Inc., graphic

1,039 followers

ST-001 has received Orphan Drug Designation from the FDA for the treatment of CTCL (a form of T-cell NHL). This designation is given to drugs targeting rare diseases affecting fewer than 200,000 people in the US. Orphan Drug Designation provides incentives to develop treatments for these conditions, which often lack adequate therapeutic options. Currently in Phase 1 clinical trials, ST-001 aims to address the significant unmet medical needs of patients with this rare and challenging disease. #ST001 #OrphanDrug #FDA #raredisease #scitechSDP #scitechdevelopment #oncology #nanofenretinide #fenretinide #lymphoma #nonhodgkin #drugdelivery #ST001

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics